The mannose-6-phosphate analogue, PXS64, inhibits fibrosis via TGF-β1 pathway in human lung fibroblasts  by Schilter, Heidi et al.
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a  b  s  t  r  a  c  t
Idiopathic  pulmonary  ﬁbrosis  (IPF)  is  a chronic  disease  characterised  by  a progressive  decline  in  lung
function  which  can be attributed  to  excessive  scarring,  inﬂammation  and  airway  remodelling.  Mannose-
6-phosphate  (M6P)  is a strong  inhibitor  of  ﬁbrosis  and  its  administration  has  been  associated  with
beneﬁcial  effects  in  tendon  repair  surgery  as well  as  nerve  repair  after  injury.  Given  this  promising
therapeutic  approach  we  developed  an  improved  analogue  of  M6P,  namely  PXS64,  and  explored  its  anti-
ﬁbrotic  effects  in  vitro.  Normal  human  lung  ﬁbroblasts  (NHLF)  and  human  lung  ﬁbroblast  19  cells  (HF19)
were  exposed  to active  recombinant  human  TGF-1  to induce  increases  in ﬁbrotic  markers.  rhTGF-1
increased  constitutive  protein  levels  of ﬁbronectin  and  collagen  in the NHLF  cells,  whereas  HF19  cells
showed  increased  levels  of ﬁbronectin,  collagen  as well  as  SMA  (alpha  smooth  muscle  actin).  PXS64
demonstrated  a  robust inhibitory  effect  on  all proteins  analysed.  IPF patient  ﬁbroblasts  treated  with  PXS64
presented  an improved  phenotype  in  terms  of  their  morphological  appearance,  as  well  as a decrease  in
ﬁbrotic  markers  (collagen,  CTGF,  TGF-3,  tenascin  C,  SMA  and  THBS1).  To  explore  the  cell signalling
pathways  involved  in  the  anti-ﬁbrotic  effects  of PXS64,  proteomics  analysis  with  iTRAQ  labelling  was
performed  and  the  data  demonstrated  a  speciﬁc  antagonistic  effect  on the  TGF-1  pathway.  This  study
shows  that  PXS64  effectively  inhibits  the  production  of  extracellular  matrix,  as  well  as  myoﬁbroblast
differentiation  during  ﬁbrosis.  These  results  suggest  that  PXS64  inﬂuences  tissue  remodelling  by inhibi-
ting  TGF-1  signalling  in  NHLF  and HF19  cell  lines,  as  well  as  in  IPF  patient  ﬁbroblasts.  Thus  PXS64  is  a
potential  candidate  for preclinical  application  in  pulmonary  ﬁbrosis.
© 2015  The  Authors.  Published  by  Elsevier  B.V. This  is  an  open  access  article  under  the  CC  BY-NC-ND. Introduction
Idiopathic pulmonary ﬁbrosis (IPF) is a progressive and
rreversible lung disease characterised by extensive scarring,
nﬂammation and airway remodelling which results in marked dis-
ortion of lung architecture and the loss of respiratory function.
lthough the molecular mechanisms underlying IPF are largely
∗ Corresponding author at: Pharmaxis, 20 Rodborough Road, Frenchs Forest, 2086
SW, Australia. Tel.: +61 2 94547283.
E-mail address: heidi.schilter@pharmaxis.com.au (H. Schilter).
ttp://dx.doi.org/10.1016/j.imlet.2015.04.003
165-2478/© 2015 The Authors. Published by Elsevier B.V. This is an open access article 
/).license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
unknown, it is proposed that the disease likely results from uncon-
trolled wound healing due to lung injury. A process, that if not
reversed, can lead to aberrant proliferation of ﬁbroblasts and exces-
sive deposition of extracellular matrix (ECM).
Fibroblasts are an abundant cell type in the lung and play a
central role in the maintenance of normal tissue function and struc-
tural integrity through controlled wound healing, proliferation and
extracellular matrix production [1,2]. However, during ﬁbrosis,
they assume a migratory, proliferative, and ultimately a proﬁbrotic,
myoﬁbroblastic phenotype [3]. Airway ﬁbroblasts have the poten-
tial to synthesise and release latent TGF- (LTGF-) [4,5], which
requires activation before it binds to its cognate receptor to exert
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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ts biological effect. Active TGF- is often overexpressed in disease
tates [6–10] and its excessive production and activation enhances
brosis progression by modulating ﬁbroblast growth, migration
nd transformation [11–16].
Unfortunately currently available pharmacological interven-
ions are unable to reverse disease pathogenesis during ﬁbrosis.
 potential therapeutic approach is the use of the phosphosugar
annose-6-phosphate (M6P) (Fig. 1, A), as it has been shown to
e a strong inhibitor of ﬁbrosis in a variety of animal models.
peciﬁcally, M6P  possesses regenerative effects in ﬂexor tendons
uring repair surgery [17–19] and enhances nerve repair during
njury [20–22]. Early research with a M6P  formulation acceler-
ted re-epithelialisation, reduced redness and improved overall
kin appearance (Renovo Group plc). Recently Adaprev treat-
ent, a hypertonic solution containing M6P, was shown to reduce
dhesions and improve collagen organisation following tendon
njury in vivo [23]. Interestingly, the action of M6P  is not spe-
iﬁc to ﬁbrosis, as this treatment also conferred protection against
xperimental autoimmune encephalomyelitis (EAE) [24], arthritis
25] and peritonitis [26]. In addition, M6P  inhibited thyroid allo-
raft rejection by reducing leukocyte inﬁltration into the grafts
26].
Based on these promising applications, we sought to develop an
mproved analogue of M6P, namely PXS25 (Fig. 1, B), with increased
hemical and metabolic stability. Its efﬁcacy was tested in the
brotic diabetic nephropathy in vitro model [27]. Upon PXS25 expo-
ure, the secretion of matrix proteins was signiﬁcantly dampened
27]. Despite these encouraging preliminary results, the highly
ydrophilic nature of PXS25 conferred low cell permeability and
imited bioavailability following oral administration. To overcome
his issue and improve the physicochemical properties of PXS25, a
ipophilic prodrug (namely PXS64, Fig. 1C), was synthesised. Due
o its characteristics, PXS64 is able to quickly diffuse across mem-
ranes and be hydrolysed into PXS25.
The present study shows that the mannose-6-phosphate ana-
ogue PXS64 effectively inhibited the production of ECM proteins, as
ell as myoﬁbroblast differentiation during TGF-1-driven ﬁbro-
is. Mechanistic studies using proteomics with iTRAQ labelling
nd mass spectrometry quantitation indicate a speciﬁc antagonis-
ic effect of PXS64 on the TGF-1 pathway. These results identify
XS64 as a potential candidate for clinical application to reduce
CM deposition in pulmonary ﬁbrosis.
. Methods
.1. Compound chemical properties
Replacement of the hydrolytically labile phosphate moiety of
annose-6-phosphate with a phosphonate bioisostere, as well as
ntroduction of a lipophilic group at the anomeric position, led
o the development of PXS25. Further derivatisation of PXS25,
ia preparation of the corresponding bis(pivaloyloxymethyl) ester
bis(POM) ester] then provided PXS64. This modiﬁcation was  made
o as to increase the associated clogP value of PXS64 (relative to
XS25) and thus improve the physicochemical proﬁle of the com-
ound.
.2. Cell culture
.2.1. Culture
NHLF cells are a human primary lung ﬁbroblast cell line pur-hased from Lonza. NHLF were maintained in Lonza custom FBM-2
edia (ﬁbroblast basal media) with additional Lonza SingleQuots
upplements (FGM-2) containing insulin, recombinant GFG-B, GA-
000 and FBS and incubated at 37 ◦C with 5% CO2.etters 165 (2015) 90–101 91
HF19 is an immortalised human lung ﬁbroblast cell line and
was purchased from Cell Bank, Australia. HF19 ﬁbroblasts were
maintained in MEM  media (In Vitro Technologies) containing peni-
cillin G, streptomycin (50 units/mL and 50 g/mL respectively),
l-glutamine (2 mM),  10% heat-inactivated foetal calf serum (FCS)
and non-essential amino acids (100 M)  and incubated at 37 ◦C
with 5% CO2.
Primary lung ﬁbroblasts from normal (CCL-201; CCL-204) and
IPF patients (CCL-134; CCL-191) were purchased from and cultured
as recommended by ATCC. Cell cultures were used within passage
6. The IPF cells originate from young IPF patients and have been
published previously [28].
Human CIMPR-positive mouse ﬁbroblasts were generated from
CIMPR-negative mouse ﬁbroblasts [29] through the retroviral
expression system as described elsewhere [30]. Mouse ﬁbroblasts
were cultured in RPMI 1640 medium supplemented with penicillin,
streptomycin, glutamine, and 10% fetal calf serum under standard
conditions.
2.2.2. Cell density
Cells were seeded into 6-well plates at 1 × 105/well and
2 × 105/well to reach subconﬂuence and overconﬂuence, respec-
tively.
2.2.3. Experimental procedure
The day prior to experiment, ﬁbroblasts were starved in 0.1% FCS
(starving media) and corresponding supplements. In a pilot study
rhTGF-1 was tested in the HF19 cells at different concentrations:
1, 2 and 10 ng/mL (e-biosciences). While 1 ng/mL was not effective,
2 and 10 ng/mL induced comparable effects. In following exper-
iments rhTGF-1 was  used at 2 ng/mL. Pirfenidone (Sigma) was
used at 50 g/mL.
For pre-, co- and post-incubation experimental setups, com-
pounds were added to the cell culture as indicated in Section 3.
2.3. Protein extraction and Western blot analysis
Fibroblasts were washed twice with PBS, scraped and lysed
in cell lysis buffer containing 20 mM Tris, 150 mM NaCl chloride,
50 mM NaF, 1 mM EDTA and 1% Triton, 1× Complete© protease
inhibitor and 1× protease inhibitors. The samples were stored at
−20 ◦C until analysis. Total protein was  determined using Quant-
iT assay (Invitrogen) as per the manufacturer’s instructions. All
cell lysates were adjusted to equal total protein levels. The sam-
ples (45 L) were mixed with sample buffer (15 L) containing
10 mM -mercaptoethanol, heated to 100 ◦C for 5 min, and sep-
arated by 10% Bis–Tris or 4–12% Bis–Tris NuPAGE gel (Invitrogen)
using MOPS buffer. Gels were transferred to PVDF membranes for
blotting. Afterwards, the membranes were incubated with primary
antibody: polyclonal anti-human SMA  (Abcam, 1:400), polyclonal
anti-human collagen (Abcam, 1:1000), polyclonal anti-human
ﬁbronectin (Abnova, 1:1000) or polyclonal anti-mouse Tubulin
(Sigma, 1:2000) in 1% BSA in PBS–Tween (0.1%) overnight. The
membrane was then washed three times with PBS–Tween (0.1%)
using Millipore SNAP i.d. vacuum and incubated with correspond-
ing secondary antibodies conjugated to horseradish peroxidase
(HRP) 1:1000. The fusion system was  used to acquire membrane
chemiluminescence, and signals were analysed by Image J against
the tubulin control.
2.4. RNA isolation and real-time PCR analysisIPF cells. Total RNA was  isolated using Trizol (Invitrogen). DNAs
were removed using Turbo DNA-free kit (Ambion). RNA was  sub-
jected to cDNA synthesis (Invitrogen) and quantitative real-time
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hemDraw Ultra, version 12.
qRT)–PCR using SYBR Green Master Mix. Quantitative gene expres-
ion was performed using 50 ng complementary DNA per reaction.
rimers to measure gene expression were purchased from IDT.
eactions were performed on the ABI 7900HT real-time PCR Sys-
em (Applied Biosystems) at the Davis Heart and Lung Research
nstitute, Ohio State University (Columbus, OH). A list of quantita-
ive RT-PCR primers can be found below. GAPDH was used as the
eference gene.
CIMPR cells. Total RNA was extracted with the PureLink RNA
ini Kit according to the manufacturer’s instructions (Ambion),
ollowed by the cDNA synthesis using SuperScript VILO cDNA
ynthesis Kit (Invitrogen). Gene expression was measured by the
-CT method based on quantitative real-time PCR using CFX96
eal-Time PCR system (Bio-Rad) with the ABI TaqMan primer sets
or mouse GAPDH and ﬁbronectin speciﬁed below. Results are
eported relative to the values for DMSO-treated CIMPR−/− cells,
hich were set to 1.
GENE Sequence
Collagen 1a1 5′-CCCCTGGAAAGAATGGAGATG-3′ Forward
5′-TCCAAACCACTGAAACCTCTG-3′ Reverse
Connective Tissue
Growth Factor
5′-ACCAATGACAACGCCTCC-3′ Forward
5′-TTGGAGATTTTGGGAGTACGG-3′ Reverse
Transforming Growth
Factor 3
5′-AGTGGCTGTCCTTTGATGTC-3′ Forward
5′-CACCTCGTGAATGTTTTCCAG-3′ Reverse
TENASCIN C 5′-CACTACACAGCCAAGATCCAG-3′ Forward
5′-TCGTGTCTCCATTCAGCATTG-3′ Reverse
Fifbronectin 5′-ACTGTACATGCTTCGGTCAG-3′ Forward
5′-AGTCTCTGAATCCTGGCATTG-3′ Reverse
Smooth Muscle Actin
(alpha)
5′-AGGAGTGGTTGCTGAATGAG-3′ Forward
5′-GTCTCATAGTCCTTCTGTCGC-3′ Reverse
Thrombospondin1 5′-CTCCCCTATGCTATCACAACG-3′ Forward
5′-AGGAACTGTGGCATTGGAG-3′ Reverse
Glyceraldehyde-3-
phosphate
dehydrogenase
5′-ACATCGCTCAGACACCATG-3′ Forward
5′-TGTAGTTGAGGTCAATGAAGGG-
3′
Reverse
GENE ABI taqman probe
Fibronectin Mm 01256744-m1
Glyceraldehyde-3-phosphate dehydrogenase 4352932E
.5. Sample preparation for proteomic analysis
Fibroblasts were plated at 80% density and incubated with
0 M of PXS64 30 min  prior to the addition of rhTGF-1 (2 ng/mL).
fter 4 h, ﬁbroblasts were washed gently twice with phosphate-
uffered saline (PBS), before replacing with fresh starve media and
ncubating for a further 20 h.e; (B) PXS25 and (C) PXS64. The calculated log P (clogP) values were derived using
At harvest, crude cellular protein extracts were obtained by
lysing ﬁbroblasts in a buffer containing 20 mM HEPES-NaOH
(pH8.0), 150 mM NaCl, 50 mM NaF, 1 mM EDTA, 1% SDS with 1x
Complete© protease and phosphatase inhibitors. Samples were
then subjected to trichloroacetic acid (TCA)/acetone precipitation.
A fresh TCA solution was prepared before the extraction process.
Solutions were mixed in a 1:8:1 ratio in the following order:
1 mL  cell lysate + 8 mL  100% ice-cold acetone + 1 mL  100% TCA and
precipitated at −20 ◦C for 1 h. Samples were then centrifuged at
18,000 × g for 15 min  at 4 ◦C. Supernatant was  discarded and pel-
lets were washed with 1 mL  ice-cold acetone and re-centrifuged
at 18,000 × g for 15 min  at 4 ◦C. The pellet was  dried at room tem-
perature. 45 g of each sample was reduced with TCEP, alkylated
with MMTS  and digested with trypsin. Samples were labelled using
iTRAQ 4-plex reagents for 1 h following the manufacturer’s instruc-
tions (ABSciex) and as previously described [31,32]. Samples were
then combined at 1:1 ratios.
2.5.1. Strong cation exchange HPLC
The iTRAQ labelled peptides were fractionated by SCX HPLC
using a PolyLC PolySulfoethyl A (200 mm × 2.1 mm × 5 m,  200 A˚)
column. The buffer A was 5 mM phosphate 25% acetonitrile, pH 2.7
and buffer B was  5 mM phosphate 350 mM KCl 25% acetonitrile, pH
2.7. After sample loading and washing with buffer A, buffer B con-
centration increased from 10% to 45% in 70 min  and then increased
quickly to 100% for 10 min  at a ﬂow rate of 300 l/min. The eluent
from SCX was collected every ½ min  at the beginning of the gradi-
ent and at 4 min  intervals thereafter. SCX fractions were dried by
vacuum centrifugation.
2.5.2. NanoLC ESI MS/MS data acquisition
The SCX fractions were resuspended in 40 L of load-
ing/desalting solution (0.1% triﬂuoroacetic acid and 2% acetonitrile
97.9% water). 39 L of the resuspended solution was loaded on
a reverse phase peptide Captrap (Michrom Bioresources) and
desalted. After desalting, the trap was  switched on line with a
150 m × 10 m C18 3 m 300A ProteCol column (SGE). The buffer
solution A was 99.9% water/0.1% formic acid and buffer solution B
was 90% acetonitrile/9.9% water/0.1% formic acid. The buffer B con-
centration was increased from 5% to 90% in 120 min  in three linear
gradient steps to elute peptides. After peptide elution, the column
was cleaned with 100% B for 15 min  and then equilibrated with
buffer A for 30 min  before the next sample injection. The reverse
phase NanoLC eluent was  subject to positive ion nanoﬂow electro-
spray analysis in an information dependant acquisition (IDA) mode
using a QSTAR Elite mass spectrometer (AB Sciex). In IDA mode
a TOFMS survey scan was  acquired (m/z 370–1600, 0.5 s), with
the three most intense multiply charged ions (counts >70) in the
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Fig. 2. Normal human lung ﬁbroblast protein expression after rhTGF-1 stimu-
lation. rhTGF-1 increased protein levels of ﬁbronectin and collagen while the
expression of SMA  (alpha smooth muscle actin) was not signiﬁcantly increased.
(A)  Quantiﬁcation was  relative to tubulin and normalised as a % of the non-TGF-1
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Fig. 3. Normal human lung ﬁbroblast protein expression after PXS64 treatment. (A)
NHLF cells were pre-treated with PXS64, followed by stimulation with rhTGF-1.
PXS64 at 10 M demonstrated a robust inhibitory effect of ﬁbronectin and collagen.
Quantiﬁcation was relative to tubulin and normalised as a % of the TGF-1 group. (B)
Representative blot of ﬁbronectin and collagen increases upon rhTGF-1stimulation
and the dose dependent response of PXS64. (C) NHLF cells were treated with PXS64
at  different times and stimulated with rhTGF-1. Compound continuous occurred
when ﬁbroblasts were pre-equilibrated with PXS64 for 30 min  and PXS64 main-
tained in culture until the end of the experiment (24 h). Pos-stimulus denominates
when PXS64 was  added to the ﬁbroblasts after 4 h of rhTGF-1 stimulation and
maintained in culture until the end of the experiment (24 h). Pre-stimulus occurred
when ﬁbroblasts were exposed to PXS64 for 1 h, PXS64 was then removed and then
stimulated to rhTGF-1. PXS64 at 10 M demonstrated a robust inhibitory effect of
ﬁbronectin protein expression independent of treatment time. Data presented areroup. (B) Representative blot of ﬁbronectin, collagen and SMA  expression upon
hTGF-1stimulation. Data presented are S.E.M. of ≥3 independent experiments
sing single cultured experiments. **p < 0.01 compared to non-TGF-1.
urvey scan sequentially subjected to MS/MS  analysis. MS/MS spec-
ra were acquired in the mass range m/z  100–1600.
.5.3. Data processing
The MS/MS  data were submitted to ProteinPilot V4.0 (AB Sciex)
or peptide identiﬁcation and quantitation using Swiss-prot human
atabase. Bias correction was selected to normalise iTRAQ inten-
ities for each sample. False discovery rate analysis was  enabled.
fter ProteinPilot data processing, protein and peptide summaries
ere exported as text ﬁles. Proteins with larger than 1.3 unused
core (better than 95% conﬁdence) were used for further protein
uantitation statistical analysis.
.6. Statistical analysis
Unless otherwise stated, data presented are mean ± S.E.M. of ≥3
ndependent experiments using single cultured experiments. A sig-
iﬁcant difference between control and multiple treatment groups
as assessed by one-way ANOVA using Dunnett’s post hoc test for
ultiple comparisons. Comparisons of two groups were performed
y unpaired student’s t test.
. Results
.1. rhTGF-ˇ1 enhanced the expression of ﬁbrotic makers in
ormal human lung ﬁbroblasts
In response to active TGF-1, lung ﬁbroblasts undergo a pheno-
ypic transformation which is associated with tissue remodelling,
ncreased expression of collagen, ﬁbronectin and  smooth mus-
le protein (SMA) as well as increased proliferative state and
odule formation [34–38]. All of which can be replicated in vitro
33]. In the present study rhTGF-1 was utilised in vitro to model
hanges associated with ﬁbrosis in normal human lung ﬁbroblastsS.E.M. of ≥3 independent experiments using single cultured experiments. **p  < 0.01
*p  < 0.05 compared to TGF-1.
(NHLFs). NHLFs were seeded at subconﬂuency (80%) and treated
with 2 ng/mL of rhTGF-1. Four hours after addition of the cytokine,
the ﬁbroblasts were gently washed and maintained in culture for
20 h.rhTGF-1 increased protein levels of ﬁbronectin and collagen
(Fig. 2A/B) by two  and four fold compared to unstimulated ﬁbro-
blasts, respectively. The expression of SMA  was not signiﬁcantly
increased (Fig. 2A/B); as such this marker was not further evaluated
in this cell line.
94 H. Schilter et al. / Immunology Letters 165 (2015) 90–101
Fig. 4. Idiopathic pulmonary ﬁbrosis patient ﬁbroblasts after PXS64 treatment.
IPF  patient ﬁbroblasts (IPF 134, IPF 191 from Lonza) were treated with 10 M of PXS64 for 24 h. Cellular morphology was  assessed at 24 and 36-h time points. The ﬁbroblasts
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tresented an improved phenotype in terms of their morphological appearance aft
XS64  was no longer present in the medium.
These initial studies established that active recombinant TGF-
1 at 2 ng/mL for a pulse of 4 h caused maximal stimulation and
herefore this protocol was utilised in further studies.
.2. Effects of PXS64 on rhTGF-ˇ1 stimulated NHLFs
Based on previous studies by Wong et al. [27], in which the M6P
nalogue PXS25 was shown to effectively inhibit ﬁbrosis, it was
ypothesised that PXS64 would also have the capacity to decrease
hTGF-1 ﬁbrotic effects on NHLFs.
NHLF cells were pre-equilibrated with PXS64 for 30 min  prior
o the addition of rhTGF-1. After 4 h, rhTGF-1 was  removed and
broblasts were maintained in medium containing PXS64; the cells
ere then incubated for the next 20 h. PXS64 demonstrated a sig-
iﬁcant inhibition of ﬁbrotic markers, with the highest efﬁcacy
bserved at 10 M (Fig. 3A/B); at this concentration it supressed
bronectin expression by 53% ± 12% (SEM) **p < 0.01 and of colla-
en by 86% ± 3% (SEM) *p < 0.05 (Fig. 3A/B). PXS64 exhibited a steep
ose response curve in reducing ﬁbrotic gene expression with the
ptimal concentration at 10 M.  Given the prominent and consis-
ent inhibitory effect associated with 10 M of PXS64, this dose was
elected for subsequent mechanistic studies.
In order to determine whether continuous treatment of ﬁbro-
lasts with PXS64 was necessary for its anti-ﬁbrotic effect, the
broblasts were exposed to PXS64 for only 60 min  prior to rhTGF-
1 stimulation. Interestingly, with only a brief pulse followed by
wo washes to remove the compound from the supernatant, PXS64
emonstrated a robust inhibitory effect of ﬁbronectin (Fig. 3C, com-
ound pre-stimulus) thus indicating a lasting effect mediated only
y a transitory exposure to the compound.
In previous experiments, PXS64 was administered prior to
ytokine stimulation. To rule out the possibility that PXS64
omehow inhibited cell priming (i.e. blocking active TGF-1 inter-
alisation, thus preventing cell activation) ﬁbroblasts were pulsed
ith PXS64 after 4 h of rhTGF-1 addition. In this instance,
he treatment was found to reverse the effects of rhTGF-1 on of PXS64 treatment. This effect was sustained even at the 36-h time point, when
ﬁbronectin (Fig. 3C, compound post-stimulus), indicating that
PXS64 does not impede cell activation or priming, but rather
reduces TGF-1 downstream signalling.
3.3. Effects of PXS64 on idiopathic pulmonary ﬁbrosis patient
lung ﬁbroblasts
To relate the effects of PXS64 to human disease, human lung
ﬁbroblasts from IPF patients were next cultured. IPF ﬁbroblasts
have altered expression in ubiquitination-mediators, proteasomal
constituents, Wnt  signalling, apoptosis, metabolic pathways and
cell cycle regulators. Although IPF cells can be stimulated by rhTGF-
1, they constitutively produce a plethora of cytokines and growth
factors and thus do not require exogenous rhTGF-1 stimulation
to activate ﬁbrotic markers [39,40]. The ﬁbroblasts were treated
with 10 M of PXS64 for 24 h and ﬁbrotic markers were analysed
at either the 24 or 36-h time points.
After 24 h, the ﬁbroblasts presented an improved phenotype in
terms of their morphological appearance. In the presence of PXS64
they changed from a senescent, growth-arrested state (as expected
to be seen in IPF ﬁbroblasts) to a regular fusiform, healthy phe-
notype (Fig. 4). Even when ﬁbroblasts were no longer in contact
with the compound (36-h time point, 12 h without PXS64) anti-
ﬁbrotic effects were still observable, suggesting that the cells did
not require continuous exposure to PXS64 (Fig. 4). mRNA analy-
sis of IPF cells demonstrated that a number of ﬁbrotic associated
genes, such as collagen, connective tissue growth factor (CTGF),
TGF-3, tenascin C, SMA  and thrombospondin 1 (THBS1), were
down-regulated by PXS64 treatment (Table 1). Importantly, ﬁbrotic
mRNA expression was  further decreased after 36 h, i.e. even when
the ﬁbroblasts were no longer in contact with PXS64. This suggested
a long lasting inhibitory effect of PXS64 on these cells. Furthermore,
collagen, TGF-3, tenascin C and ﬁbronectin inhibition were actu-
ally greater at the 36-h time point, providing further support of the
anti-ﬁbrotic efﬁcacy of PXS64.
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Fig. 5. H19 (human lung ﬁbroblast) protein expression after rhTGF-1 and PXS64 treatment. (A) HF19 cells were treated with rhTGF-1 and cells showed increased protein
levels  of SMA  (alpha smooth muscle actin), ﬁbronectin, and collagen. Quantiﬁcation was relative to tubulin and normalised as a % of the non-TGF-1 group ***p < 0.01
**p  < 0.01 compared to non-TGF-1  group. (B) Representative blot of SMA, ﬁbronectin and collagen increases upon rhTGF-1stimulation. (C) HF19 cells were pre-treated
with  PXS64, followed by stimulation with rhTGF-1. PXS64 at 10 M demonstrated a robust inhibitory effect of all proteins tested. Quantiﬁcation was  relative to tubulin
and  normalised as a % of the TGF-1 group. (D) Representative blot of SMA  and collagen increases upon rhTGF-1stimulation and dose dependent response of PXS64. (E)
HF19 cells were seeded at 80% conﬂuency and treated with PXS64 or Pirfenidone, PXS64 exhibited a very potent anti-ﬁbrotic activity comparable to the effect mediated by
P ry pro
r pared 
u
3
s
airfenidone. (F) HF19 cells were seeded at 120% density, PXS64 still displayed inhibito
elative to tubulin and normalised as a % of TGF-1 group ***p < 0.01 **p < 0.01 com
sing  single cultures.
.4. Effects of PXS64 on cell densityA number of studies have suggested that cell den-
ity inﬂuences cell behaviour upon stimulation [41–45],
s such the action of PXS64 was tested in a high densityperties, in contrast to the lack of effect displayed by Pirfenidone. Quantiﬁcation was
to the TGF-1 group. All data presented are S.E.M. of ≥3 independent experiments
environment by seeding ﬁbroblasts at 120% conﬂuency. How-
ever, normal human lung ﬁbroblasts did not proliferate
under these conditions. Further studies were therefore per-
formed on HF19 cells, an immortal human lung ﬁbroblast
line.
96 H. Schilter et al. / Immunology Letters 165 (2015) 90–101
Table 1
Idiopathic pulmonary ﬁbrosis patient ﬁbroblasts after PXS64 treatment IPF patient
ﬁbroblasts were treated with 10 M of PXS64 for 24 h. mRNA expression of ﬁbrotic
markers was  assessed at 24 and 36-h time points. A number of ﬁbrotic markers
were down-regulated by PXS64 treatment. It was found that the expression was
further decreased after 36 h, even when the ﬁbroblasts were no longer in contact
with PXS64. Data presented are from one experiment using single culture.
Compared to IPF control
24 h Post PXS64 36 h Post PXS64
Collagen −40% −70%
Connective tissue growth factor −45% −52%
TGF-3 −30% −83%
Tenascin C −11% −42%
Fibronectin +4% −49%
SMA  −82% −51%
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Table 2
Proteomics analysis of HF19 upon rhTGF-1 stimulation Fibroblasts were
treated with rhTGF-1 for 4 h, and proteomics analysis was done at the 24-h
time point. Protein values were calculated as a ratio between two  groups of
interest. To be regarded as signiﬁcant, proteins were required to be a true
value (as assessed by Ingenuity software) and considered highly regulated
(≤0.83 for down-regulated proteins or ≥1.2 for up-regulated proteins). Upon
rhTGF-1  treatment, 55 proteins were differentially regulated in the HF19
cell line. The proteins highlighted by the asterisk are similarly regulated
by  rhTGF-1 in the NHLF cells. Data presented are from two independent
experiments using single cultures.Thrombospondin 1 −69% −43%
Firstly, HF19 cells were found to be sensitive to active rhTGF-
1 as the expression of ﬁbrotic markers increased upon stimulus
ith rhTGF-1 (Fig. 5A/B). In contrast to NHLFs, SMA  expression
ncreased in HF19 after rhTGF-1 treatment, indicating differences
etween the two cell types. In a similar manner to NHLFs, HF19
ells were treated with different doses of PXS64, and the effect at
0 M was found to be maximal (Fig. 5C/D).
HF19 cells were then seeded at different conﬂuences and
ere also treated with Pirfenidone, a small molecule with
ell documented anti-ﬁbrotic activities. When ﬁbroblasts were
eeded at 80% conﬂuency, PXS64 exhibited a very potent
nti-ﬁbrotic activity (as measured by the inhibition of SMA,
bronectin and collagen) comparable to the effect mediated by
irfenidone (Fig. 5D/E). Moreover, when the ﬁbroblasts were
eeded at overconﬂuency, PXS64 maintained inhibitory proper-
ies, in contrast to the lack of effect displayed by Pirfenidone
Fig. 5F).
.5. PXS64 acts independently of cation-independent mannose
-phosphate receptor (CIMPR)
Multiple reports have described the M6P  dependent activa-
ion of latent TGF-1 [46–48], which is thought to occur through
he M6P-binding sites on CIMPR (cation-independent mannose
-phosphate receptor) [48]. It was therefore anticipated that
XS64 could also inhibit TGF-1 signalling through CIMPR as
as also postulated for PXS25 [27]. As such, mouse CIMPR−/−
broblasts (Fig. 6A) and mouse CIMPR−/− ﬁbroblasts reconsti-
uted with human CIMPR (Fig. 6B) were pre-treated with 10 M
f PXS25, PXS64 or mannose-6-phosphate (M6P) followed by 4 h
ncubation with rhTGF-1. After rhTGF-1 removal, ﬁbroblasts
ere incubated with the corresponding inhibitor and analysis
as performed at the 24-h time point. Interestingly, whilst nei-
her PXS25 nor M6P  showed any effects, PXS64 was found to
educe ﬁbronectin levels in the CIMPR−/− ﬁbroblasts (Fig. 6A),
hereby suggesting a divergent mechanism by which PXS64 can
xert ant ﬁbrotic effects. To further explore this observation
IMPR−/− ﬁbroblasts were reconstituted with human CIMPR
Fig. 6B). Once again either PXS25 or M6P  did not inhibit rhTGF-
1-induced ﬁbronectin expression in this ﬁbroblast cell line. In
ontrast, PXS64 demonstrated a reduction in ﬁbronectin. Simi-
ar results were obtained in immunoblotting analyses (data not
hown).
Taken together these results show that PXS64 acts indepen-
ently of CIMPR and that there are clear differences between the
echanism of action displayed by PXS64 when compared with
XS25 and M6P.3.6. PXS64 is an antagonist on the TGF-ˇ1 pathway
To elucidate the underlying mechanism of PXS64 action, pro-
teomic proﬁling of HF19 and NHLF cells was performed. The
composition of the ﬁbroblast proteome resulted in the identiﬁca-
tion of over 1200 proteins (FDR 0.1% by ProteinPilot FDR analysis
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Fig. 6. CIMPR deﬁciency does not affect PXS64 treatment. Mouse ﬁbroblasts were pre-treated with 10 M of PXS25, PXS64 or mannose-6-phosphate (M6P), followed by
rhTGF-1  stimulation. The rhTGF-1 induced increase of ﬁbronectin was  diminished by PXS64 in (A) CIMPR−/− ﬁbroblasts as well as in (B) mouse CIMPR−/− ﬁbroblasts
reconstituted with human CIMPR. Data presented are S.E.M. of ≥2 independent experiments using single cultures. **p < 0.01 *p < 0.05 compared to the TGF-1 group.
Table 3
Proteomics analysis of NHLF upon rhTGF-1 stimulation Fibroblasts were treated with rhTGF-1 for 4 h, and proteomics analysis was  done at the 24-h time point.
Protein values were calculated as a ratio between two groups of interest. To be regarded as signiﬁcant, proteins were required to be a true value (as assessed by
Ingenuity software) and considered highly regulated (≤0.83 for down-regulated proteins or ≥1.2 for up-regulated proteins). Upon rhTGF-1 treatment, 82 proteins were
differentially regulated in the NHLF cell line. The proteins highlighted by the asterisk are similarly regulated by rhTGF-1 in the HF19 cells. Data presented are from one
experiment using single culture.
u
2
g
a
fsing decoy database), obtained from 14,097 distinct peptides and
8,303 total spectra (data not shown). To distinguish these and to
enerate a comprehensive list of proteins regulated by rhTGF-1,
 data processing pipeline was employed. Initially protein dif-
erential expression was measured as iTRAQ ratios between twogroups of interest (i.e. rhTGF-1 vs. none treated). Then, to be
regarded as signiﬁcant, proteins were required to be identiﬁed
by at least two unique peptides and considered highly regu-
lated (<0.83 for down-regulated proteins or >1.2 for up-regulated
proteins).
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Table 4
Proteomics analysis of HF19 upon PXS64 treatment A group of 20 proteins
was found to be regulated by PXS64, with 11 proteins being a subset from
the  group of proteins up-regulated by rhTGF-1.
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Table 5
Proteomics analysis of NHLF upon PXS64 treatment A group of 55 proteins was
found to be regulated by PXS64, with 39 proteins being a subset from the group of
proteins down regulated by rhTGF-1. Data presented are from one experiment
using single culture.Upon rhTGF-1 treatment, 55 and 82 proteins were found
o be regulated in the HF19 and NHLF cell lines respectively
Tables 2 and 3), with a commonality in 18 proteins between HF19
nd NHLF (proteins highlighted by the asterisk in Tables 2 and 3).
he functional signiﬁcance of the regulated proteins was  evaluated
y linking known proteins to their putative biological functions,
ased on their gene ontology annotations and their correlation
n the Ingenuity Knowledge Base. The top canonical pathways
egulated by rhTGF-1 in HF19 cells were ILK signalling, tight junc-
ion signalling, hepatic ﬁbrosis/hepatic stellate cell activation and
aveolar-mediated endocytosis signalling. For NHLF cells, the reg-
lated canonical pathways were eIF2, eIF4 and p70S6K signalling,
epatic ﬁbrosis/hepatic stellate cell activation, RAN signalling and
TOR signalling.
HF19 cells treated with rhTGF-1 concomitant with PXS64
howed a differential expression of 20 proteins (Table 4), none
f which were apoptotic pathways. Interestingly 11 of these pro-
eins were also a subset of the proteins regulated by rhTGF-1.
n the NHLF cells a group of 55 proteins were regulated by co-
reatment with rhTGF-1 + PXS64, with 38 being a subset regulated
y rhTGF-1 alone (Table 5). Remarkably, the majority of the pro-
eins inhibited by PXS64 returned to baseline levels. It is important
o note that none of the caspase family members or other apop-
otic related proteins (such as calpain and BCL-1) were altered after
reatment with PXS64. In addition, PXS64 was tested in a standard
ell health assay [49] and concentrations of up to 100 M showed
o signs of toxicity (data not shown).
. Discussion
The present study demonstrates that the lipophilic mannose-
-phosphate (M6P) analogue, PXS64, dampens rhTGF-1-induced
ollagen, ﬁbronectin and SMA  production by NHLF and HF19
broblasts. In addition, PXS64 is a strong inhibitor of ﬁbrotic genes
n IPF patient ﬁbroblasts. Proteomics analysis conﬁrmed that the
ction of PXS64 was speciﬁc to the TGF-1 pathway.
Fibroblast migration, proliferation and transdifferentiation
re present in normal lungs and the transformation into a
yoﬁbroblast-like cell type is regarded as an early step in the
brotic process [50,51]. Myoﬁbroblast recruitment and differen-
iation in the lung enhances scarring and ﬁbrosis, resulting in
ulmonary stiffness and impairment of lung function [12,50,52].In vitro ﬁbroblast-to-myoﬁbroblast transdifferentiation has been
shown to be induced by TGF-1 [53], thus it was  not unexpected
that stimulation of NHLF and HF19 cells with active rhTGF-1
would induce this process. However, there were distinct differ-
ences in the response of these ﬁbroblasts, with both cells showing
increases in collagen and ﬁbronectin but only HF19 (and not NHLF
cells) highly expressing SMA. This was  further conﬁrmed by pro-
teomics analysis in which rhTGF-1 regulated a number of different
proteins in HF19 compared to NHLF cells. Overall the protein
expression results served to conﬁrm that both NHLF and HF19 are
responsive to rhTGF-1 and underwent differentiation. The under-
lying mechanistic differences in protein synthesis of NHLF and HF19
logy L
w
b
b
f
c
s
n
m
ﬁ
c
a
i
s
r
P
c
w
o
t
f
n
d
s
p
v
d
w
w
s
h
c
w
e
P
t
ﬂ
P
s
d
t
t
b
w
t
[
[
ﬁ
n
w
b
a
i
a
c
i
d
b
h
s
a
s
nH. Schilter et al. / Immuno
ere not elucidated in this study. However, the dissimilarities could
e indicative of a delay in activating certain pathways, which might
e attributed to the origin of the ﬁbroblasts, or simply due to the
act that that NHLF are primary cells and HF19 are an immortalised
ell line. In fact, a number of reports have indicated inherent dis-
imilarities between primary and immortalised cells [54–56].
Idiopathic pulmonary ﬁbrosis is a condition for which there is
o effective therapy to restore structural and/or functional nor-
ality. As such, the prevention of lung scarring from excessive
broblast-to-myoﬁbroblast transdifferentiation would be of great
linical relevance. An interesting approach is the use of M6P  or the
nalogue PXS25, as they have shown great promise in variety of
nﬂammation and ﬁbrosis models [18,20–22,24–27]. In the current
tudy, the lipophilic M6P  analogue PXS64 was investigated during
hTGF-1 induced myoﬁbroblast differentiation. Treatment with
XS64 prevented induction of ﬁbrotic proteins and mRNA in all
ell types tested. Even when ﬁbroblasts were no longer in contact
ith the compound (for over 12 h) anti-ﬁbrotic effects were still
bservable, indicating a lasting effect mediated only by a transi-
ory exposure to the compound. Surprisingly, the treatment was
ound to reverse the effects of rhTGF-1, indicating that PXS64 does
ot impede cell activation or priming, but rather reduces TGF-1
ownstream signalling.
To date a number of studies have indicated that cellular den-
ity can alter the surrounding environment by inﬂuencing cellular
henotype and consequently susceptibility to therapeutic inter-
ention. As shown by Masur et al., ﬁbroblasts seeded at low
ensity produce a myoﬁbroblast population of >70%; however,
hen seeded at high density the ﬁbroblasts produced cultures
ith only 5–10% myoﬁbroblasts [41]. Furthermore, Petridou et al.
howed that the low density cultures expressed more SMA than
igh density cultures [42]. Later studies have also shown that
ell density can inﬂuence the mechanical properties of cells [43],
ith high cellular density proposed be sufﬁcient to induce qui-
scence [44,45]. In the subconﬂuent ﬁbroblast culture system,
XS64 demonstrated exceptional anti-ﬁbrotic activity, equal to
hat displayed by Pirfenidone. While in the high ﬁbroblast con-
uency model, PXS64 maintained its anti-ﬁbrotic effects whereas
irfenidone completely lost efﬁcacy. Taken together, the results
uggest that PXS64 inhibits ﬁbrotic protein expression indepen-
ent of the speed at which myoﬁbroblasts are differentiating or
he status of cellular quiescence.
Whilst the exact mode of action of PXS64 was  not determined,
he ﬁndings from this study provide important clues as to what may
e occurring. The action of M6P  itself has proven controversial as it
as originally proposed to occur via its membrane bound recep-
or (cation independent mannose-6-phosphate receptor/CIMPR)
17,57] however more recent studies have described otherwise
23,58]. Wong et al. demonstrated that TGF-1 activation in corneal
broblasts was M6P  independent [23], while Barnes et al. showed
o evidence of CIMPR in M6P  treated tissue [58]. Nevertheless, it
as important to address whether M6P  and its analogues could
lock the binding of latent TGF- binding to CIMPR, inhibit its
ctivation and, consequently, any downstream signalling events
n ﬁbroblasts. Notably, in the cellular model used in this study,
ctive rhTGF-1 was added directly to the ﬁbroblasts, thereby cir-
umventing the latent TGF-/CIMPR interaction and consequently
ndicating that the inhibitory effect of PXS64 was  not, in actual fact,
ependent on CIMPR. In addition, in both CIMPR-negative ﬁbro-
lasts as well as CIMPR-negative ﬁbroblasts ectopically expressing
uman CIMPR, PXS64 inhibited TGF-1 induced ﬁbronectin expres-
ion. Based on these observations, CIMPR does not appear to have
ny contribution to the pathways blocked by PXS64.
It is noteworthy that whilst the lipophilic M6P  analogue PXS64
trongly inhibited TGF-1-induced ﬁbronectin expression, M6P
or the more polar M6P  analogue PXS25 had an effect. These resultsetters 165 (2015) 90–101 99
are in contrast to what has been previously described, whereby
M6P  and PXS25 were shown to effectively inhibit disease mod-
els [18,20–22,24–27]. Although we  currently cannot fully explain
these observations, a possibility could be due to variances in cell
lines, activation pathways and differences in cell membrane perme-
ability. It is also plausible that given the high lipophilicity of PXS64
(a prodrug of PXS25) it diffused across the cell membrane and, once
within the intracellular space, hydrolysed into PXS25. As such the
prolonged effect exhibited by PXS64 may, in actual fact, be due to
the intracellular presence of PXS25. In contrast, M6P  and PXS25
are not highly permeable and thus any intracellular concentrations
would potentially have been too low to demonstrate an effect.
Having ruled out CIMPR as a putative target of PXS64, protein
analysis of NHLF and HF19 cells upon active rhTGF-1 treatment
was established in an attempt to identify the pathways/signalling
events involved in the mode of action. Although there were clear
phenotypical differences between these ﬁbroblasts, PXS64 success-
fully inhibited ﬁbrotic markers suggestive of the speciﬁc action
of PXS64 on the TGF-1 pathway. Proteins of special interest for
the biology of ﬁbrosis included thrombospondin-1, plasminogen
activator inhibitor 1, ﬁbronectin, collagen alpha-1(I) chain, col-
lagen alpha-2(I) chain, transforming growth factor-beta-induced
protein ig-h3, fermitin family homolog 2, procollagen-lysine,
2-oxoglutarate 5-dioxygenase 2, tenascin, plastin-3, caldesmon,
catenin alpha-1, prolyl 4-hydroxylase subunit alpha-2 [59–67].
These results are in agreement with the hypothesis that TGF-1
promotes the synthesis of proteins which are critical to lung ﬁbro-
sis. The other proteins were in the metabolic pathway, consistent
with the proliferative effect of TGF-1 [13,37]. It is noteworthy
that a subset of the proteins (transgelin, moesin, thioredoxin,
electron-transfer ﬂavoprotein alpha-subunit, mitochondrial pre-
cursor, NAD(P)H dehydrogenase [quinone] and nuclease sensitive
element binding protein) were also identiﬁed as part of the
protein expression of A549 human lung adenocarcinoma stim-
ulated with TGF- [68], indicative of a common downstream
process of these cells. As is evident from the changes in cell
morphology, TGF-1 mediated cytoskeletal reorganisation. These
changes in the cytoskeleton play a central role in the regulation
of cellular processes linked to anchorage, cell growth and cell
migration [62,69,70]. Of the up-regulated proteins, integrin alpha,
myosin, collagen and ﬁbronectin regulate cytoskeletal reorganisa-
tion. These proteins are also implicated in the dynamic process of
cellular motility and/or the interaction of cells with the extracel-
lular matrix. Speciﬁcally in the case of the up-regulated protein
collagen, it is recognised that its accumulation is a major feature
of pulmonary ﬁbrosis and other ﬁbrotic lesions [62]. Interestingly
PXS64 was  able to dampen these proteins, in addition to inhibiting
thrombospondin, CTGF, elongation factor 2 and tensin, fermintin
family homolog, all proteins associated with some form of ﬁbro-
sis, indicative of the anti-ﬁbrotic role of PXS64. The biological
network analysis using the Ingenuity pathway tool provided infor-
mation to link known proteins to putative biological processes
through review of the literature. This path network analysis further
strengthens the data interpretation by identifying known regula-
tory molecules of TGF-1, like ILK signalling, tight junction, RAN
and mTOR signalling.
Taken together, these results show the anti-ﬁbrotic effects of
PXS64 and highlight the potential of a lipophilic M6P  analogue as
a potential therapeutic tool, in addition to being a novel approach
to dissect the mechanisms underlying ﬁbrosis.
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